Corvus Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$43.0 | -$27.5 | -$23.4 | -$32.6 | -$38.6 |
| Net income | -$15.3 | -$62.3 | -$27.0 | -$41.3 | -$43.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$33.0 | — | -$24.0 | -$27.3 | -$36.7 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 84.1M · Free float 64.3%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.